Studies on preclinical mouse tumor models have indicated that gC1qR can be considered as a suitable target for different cancer therapy approaches, such as monoclonal antibody therapy, small molecules, CAR-T technology, and tumor vaccination (Figure 2). Here, C1QBP is linked to cancer.